Mounjaro (Tirzepatide) Research Explainer

Mounjaro gained FDA approval on May 13, 2022, and is marketed by Eli Lilly and Company, which is based in the USA. Mounjaro activates both GLP-1 and GIP receptors, while other weight loss medications like Ozempic and Wegovy only target GLP-1 receptors.

Introduction to Mounjaro

Mounjaro, also known by its generic name tirzepatide, is a once weekly injection designed to help manage type 2 diabetes in adults and children aged 10 years and older. This innovative medication works by activating two key gut hormone receptors—GIP and GLP-1—which play a crucial role in regulating blood sugar levels and insulin production. By targeting both pathways, Mounjaro helps lower blood sugar levels, improve blood sugar control, and support healthy insulin production.

In addition to its benefits for blood sugar, Mounjaro has been shown to promote weight loss, especially when used alongside diet and exercise. Many patients experience improved blood sugar and significant weight loss as part of a comprehensive treatment plan that includes lifestyle changes and regular monitoring.

How Does Mounjaro Work?

Tirzepatide is a synthetic peptide that simultaneously activates two incretin hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. This dual-agonist approach, sometimes called “twincretin” therapy, produces greater metabolic effects than activating either receptor alone.

GLP-1 Receptor Activation

The GLP-1 component suppresses appetite through hypothalamic and brainstem receptor activation, slows gastric emptying to increase satiety, and enhances glucose-dependent insulin production from pancreatic beta cells. These effects are shared with all GLP-1 receptor agonists (semaglutide, liraglutide) but tirzepatide’s GLP-1 potency is approximately 5-fold lower than native GLP-1, balanced by the additive effects of GIP co-agonism.

GIP Receptor Activation

The GIP component is what distinguishes tirzepatide from pure GLP-1 receptor agonists. GIP receptor agonism enhances insulin production and secretion, improves beta cell function, and—crucially—appears to potentiate the weight loss effect of GLP-1 through mechanisms that are still being characterised. Preclinical data suggests GIP receptor activation in the central nervous system contributes to appetite suppression, while peripheral GIP signalling may improve adipose tissue metabolism and lipid handling. For a comparison of how tirzepatide’s mechanism differs from triple-agonist compounds, see our GIP/GLP-1/glucagon pathway analysis.

Net Metabolic Effects

The combined activation produces several coordinated metabolic improvements beyond weight loss: reduced fasting insulin and improved insulin sensitivity (HOMA-IR improved by 65–72% in SURMOUNT-1), reduced triglycerides (up to 36% reduction), increased HDL cholesterol, reduced liver fat content (up to 51% reduction), lowered systolic blood pressure (6–9 mmHg), and improved inflammatory markers (C-reactive protein reduction up to 48%).

How Does Mounjaro Work to Improve Blood Sugar?

Tirzepatide helps improve blood sugar through multiple mechanisms. It enhances glucose-dependent insulin production from pancreatic beta cells, meaning insulin secretion increases only when blood sugar glucose levels are elevated. This glucose-dependent action reduces the risk of hypoglycemia compared to older diabetes treatments. Additionally, tirzepatide suppresses glucagon secretion (which normally raises blood sugar glucose), slows the rate at which food enters the small intestine, and improves peripheral insulin sensitivity.

In SURPASS programme trials, the Mounjaro injection improved blood sugar control as measured by HbA1c by up to 2.58%, with many patients achieving target glycaemic levels.

Clinical Trial Weight Loss Data

The Mounjaro injection has been evaluated across two major clinical trial programmes: SURPASS (type 2 diabetes) and SURMOUNT (obesity/overweight). Together, these programmes enrolled over 25,000 participants and established tirzepatide as the most effective approved weight loss medication, demonstrating significant weight loss across all doses. However, it is important to note that Mounjaro is not approved for weight loss, but it has shown significant weight loss effects in clinical trials and is frequently prescribed off-label for this purpose.

*SURMOUNT-3 combined tirzepatide with intensive lifestyle intervention (1,200–1,500 kcal/day diet plus 150 min/week exercise), producing the highest weight loss ever recorded in a Phase 3 obesity trial with an approved medication. When compared to other weight loss medications such as Ozempic and Wegovy, Mounjaro has demonstrated superior efficacy in clinical trials.

Key Efficacy Findings

• Dose-response relationship: Weight loss scales clearly with dose. The 15 mg dose consistently outperforms 10 mg and 5 mg across all trials
• ≥5% weight loss: Achieved by 89–91% of participants on 15 mg (SURMOUNT-1) vs 35% on placebo
• ≥20% weight loss: Achieved by 56.7% on 15 mg, 47.5% on 10 mg, and 32.1% on 5 mg (SURMOUNT-1)
• ≥25% weight loss: Achieved by 36.2% on 15 mg (SURMOUNT-1)—more than one-third of patients lost a quarter of their body weight
• Weight loss plateau: Maximum weight loss typically occurs at 60–72 weeks. Weight stabilises rather than continuing to decline indefinitely

Head-to-Head vs Semaglutide

The SURPASS-2 trial directly compared tirzepatide to semaglutide 1 mg in patients with type 2 diabetes (n=1,879). Tirzepatide 15 mg produced 13.1% weight loss vs 6.7% with semaglutide 1 mg—a nearly 2-fold difference. HbA1c reduction was also superior: −2.58% with tirzepatide 15 mg vs −1.86% with semaglutide 1 mg. While this comparison used the diabetes dose of semaglutide (not the higher Wegovy 2.4 mg dose), the margin of superiority was substantial. For a visual summary of what these trial numbers translate to in practice, see our Mounjaro before and after weight loss results. For a broader comparison including next-generation compounds, see our retatrutide vs tirzepatide vs CagriSema analysis.

Approved-Label Dose Escalation (Reference)

Approved labelling for Mounjaro and Zepbound describes a once-weekly subcutaneous schedule using a single-dose pre-filled pen, with a gradual dose-titration sequence designed to mitigate gastrointestinal events. The initiation dose is intentionally subtherapeutic for weight loss and functions primarily as a tolerability assessment. Dose adjustment, escalation pacing, and continuation belong to the prescribing clinician; the table below summarises the labelled escalation for educational reference only and should not be read as a protocol.

Approved-Label Administration Notes (Educational Reference)

The Eli Lilly Instructions for Use and approved labelling describe a single-dose pre-filled pen with a hidden needle, delivering one fixed weekly dose subcutaneously into abdomen, thigh, or upper arm, with site rotation between doses noted to reduce injection-site reactions. The labelling describes a 4-day missed-dose window, room-temperature storage tolerances of up to 21 days at 30°C, and instructs that tirzepatide must not be combined in the same syringe or pen with insulin. Sharps disposal is specified for used pens. These points are summarised here for research and educational context; any administration decision sits with the prescribing clinician and the official Lilly Instructions for Use, not with this page.

For research-context dose escalation principles applicable to incretin-class compounds, see the retatrutide dosage data review. For laboratory peptide storage requirements (a different scope from approved-medicine pen storage), see the peptide stability and storage guide.

Mounjaro Prescribing Context (Reference)

Approved Mounjaro labelling positions the medicine for type 2 diabetes management by licensed prescribers. Eligibility, baseline workup, and treatment continuation are clinical decisions made within a prescriber-patient relationship and are not a function of self-screening or this article.

Published labelling lists contraindications including a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and notes specific caution for patients with histories of pancreatitis, severe gastrointestinal disease, kidney impairment, or hypersensitivity to tirzepatide or its excipients. These are summarised for research context; eligibility and risk-benefit assessment belong to the prescribing clinician.

Mounjaro Injection Side Effects and Safety Profile

The published tirzepatide adverse-event profile is dominated by gastrointestinal events, consistent with the mechanism of action. Trial reports describe most events as mild to moderate, concentrated during dose escalation, and attenuating with continued exposure. Persistent or severe symptoms warrant evaluation by the prescribing clinician.

Clinical trial datasets also document concurrent reductions in blood pressure, improvements in lipid profile, and improved glycaemic control alongside weight loss.

Severe abdominal or back pain is a recognised warning sign for pancreatitis in published labelling and is treated as a clinical emergency under the prescriber’s direction.

Common Side Effects (SURMOUNT-1, 15 mg)

• Nausea: 33.3% (vs 6.7% placebo). Most episodes were mild and peaked during first 4–8 weeks of each dose increase
• Diarrhea: 23.0% (vs 7.3% placebo). Typically self-limiting within 1–2 weeks
• Vomiting: 12.8% (vs 2.5% placebo). More common during initial dose escalation
• Constipation: 17.1% (vs 4.8% placebo). May require dietary fibre supplementation
• Injection site reactions: 7.2% (vs 2.0% placebo). Redness, itching, or pain at injection site
• Decreased appetite: 16.0% (considered a therapeutic effect rather than adverse event by some researchers)

Reported Tolerability Patterns

Published trial reports describe gastrointestinal events — nausea, diarrhoea, decreased appetite, vomiting, mild abdominal pain — as most prominent during initial dose escalation and as generally diminishing with continued exposure. Clinical-practice mitigation strategies in the literature include gradual titration, hydration, and adjustments at the prescriber’s discretion. Severe gastrointestinal symptoms, swallowing difficulty, or breathing changes are clinical emergencies handled by the prescribing clinician, not by self-titration.

Hair Loss Signal

Alopecia has been reported in post-marketing surveillance and was not a commonly reported event in the SURMOUNT trials. The literature attributes hair shedding accompanying rapid and significant weight loss primarily to telogen effluvium, a temporary shift in the hair growth cycle driven by caloric deficit and rapid body-mass change — typically reversible after weight stabilises. Clinical management (nutrient assessment, thyroid review, etc.) sits with the prescribing clinician.

Serious Adverse Events

Serious adverse events occurred in 6.9% of tirzepatide 15 mg patients vs 5.8% on placebo in SURMOUNT-1. Rare but serious conditions related to Mounjaro injection include pancreatitis, gallbladder problems, kidney injury, severe allergic reactions, hypoglycemia, and a risk of thyroid cancer. Specific serious risks include:

• Pancreatitis: Reported in 0.1–0.2% of patients. Discontinue if suspected. All GLP-1 class medications carry this risk
• Gallbladder disease: Cholelithiasis and cholecystitis rates increase with rapid weight loss. Incidence was 1.5% with tirzepatide 15 mg vs 0.4% placebo
• Thyroid cancer (C-cell tumours): Boxed warning based on rodent studies showing thyroid medullary carcinoma with GLP-1 receptor agonists. Not confirmed in humans. Contraindicated in patients with personal or family history of medullary thyroid cancer or MEN 2 syndrome
• Hypoglycemia: Low risk as monotherapy (tirzepatide has glucose-dependent insulin secretion). Risk increases when combined with insulin or sulfonylureas

For a comprehensive side effect comparison across the GLP-1 drug class, see our Ozempic vs Mounjaro vs Wegovy side effects analysis and retatrutide safety profile.

Hypoglycaemia Signal

Approved labelling notes that tirzepatide can elevate hypoglycaemia risk when combined with other diabetes medications or insulin, with hallmark presentations including tremor, dizziness, diaphoresis, confusion, and irritability. As monotherapy, tirzepatide’s glucose-dependent insulin secretion makes hypoglycaemia uncommon. Risk stratification, monitoring frequency, and household-level safety planning belong to the prescribing clinician.

Perioperative and Sedation Context

Recent anaesthesia-society guidance describes a delayed-gastric-emptying signal with GLP-1 receptor agonists that can affect aspiration risk under deep sedation or general anaesthesia. Disclosure of tirzepatide use to the anaesthesia and surgical team is the standard clinical expectation; perioperative timing and any treatment hold are clinician-directed.

Approved-Label Safety Profile (Reference Summary)

The summary below distils published US labelling for Mounjaro and Zepbound and is provided as an educational reference. It is not a substitute for the full prescribing information, the Lilly Medication Guide, or clinical counselling from a licensed prescriber.

Labelled Contraindications

Approved labelling lists tirzepatide as contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This rests on a boxed warning derived from rodent C-cell tumour findings observed across the GLP-1 receptor agonist class. Pre-existing pancreatitis history is flagged for closer monitoring, and known hypersensitivity to tirzepatide or its excipients is also a contraindication.

Pregnancy and Lactation Notes

Animal reproduction data underpin labelled cautions for fetal harm. Approved labelling recommends discontinuation in advance of a planned pregnancy due to the compound’s long half-life, with the timing window being a clinical decision. Excretion in human milk is uncharacterised. Effective contraception during treatment in women of childbearing potential is part of standard prescriber counselling.

Oral Contraceptive Interaction

Delayed gastric emptying can reduce the absorption of oral contraceptives. Published labelling describes a clinician-directed switch to non-oral contraception or a backup barrier method during initiation and around dose escalation, when motility effects are most pronounced.

Kidney and Hydration Signal

Volume loss from gastrointestinal events can drive dehydration and, in severe cases, acute kidney injury or worsening of chronic kidney disease. Hallmark dehydration signs (dark urine, reduced output, dizziness, dry mouth) are documented in published guidance. Fluid management and renal monitoring during persistent GI symptoms or dose escalation belong to the prescribing clinician.

Diabetic Retinopathy Signal

Rapid glycaemic improvement can transiently worsen pre-existing diabetic retinopathy. SURPASS trial reports describe retinopathy complications in some treated participants. Eye-exam scheduling and treatment pacing in those with a retinopathy history are clinician-directed.

Gastroparesis and Motility Signal

Because tirzepatide slows gastric emptying, pre-existing motility disorders, including gastroparesis, can worsen. Published labelling advises caution before prescribing in patients with severe gastrointestinal motility disorders. Persistent dysphagia, severe bloating, or maldigestion is escalated to the prescriber.

Allergic Reactions

Serious allergic reactions are rare in published surveillance. Recognised features include facial, lip, tongue, or throat swelling, severe rash or pruritus, dyspnoea, tachycardia, or syncope. Such presentations are clinical emergencies and prompt discontinuation under prescriber direction. Injection-site reactions affect approximately 3–7% of treated participants and are typically mild.

Recognised Emergency Signals

Published labelling identifies several presentations as clinical emergencies in patients on tirzepatide: persistent severe abdominal pain (possible pancreatitis), severe allergic-reaction features, severe dehydration, vision changes in patients with diabetic retinopathy, and severe hypoglycaemia in combination regimens with insulin or sulfonylureas. These are evaluated and managed by the prescribing clinician or emergency services, not via self-management based on this article.

Body Composition and Muscle Preservation

One of the key clinical questions with any significant weight loss intervention is the ratio of fat mass to lean mass lost. Excessive lean mass (muscle) loss can impair functional capacity, reduce basal metabolic rate, and increase frailty risk, particularly in older adults. Healthcare providers increasingly monitor body composition alongside scale weight when prescribing the Mounjaro injection.

SURMOUNT-1 body composition substudy data (DXA analysis in a subset of participants) showed that approximately 75–82% of total weight lost with tirzepatide 15 mg was fat mass, with 18–25% being lean mass. This fat-to-lean ratio compares favourably to semaglutide (STEP 1 reported approximately 61% fat, 39% lean mass loss) and is closer to the optimal ratio seen with surgical interventions.

The GIP receptor component may contribute to this more favourable body composition outcome. Preclinical studies suggest GIP signalling in adipose tissue promotes lipid storage efficiency and may preferentially direct energy metabolism toward fat oxidation over muscle catabolism, though the precise mechanisms in humans remain under investigation. For a detailed analysis of lean mass preservation across weight loss drugs, see our GLP-1 muscle loss and body composition review.

Cardiovascular and Metabolic Benefits

Beyond significant weight loss, the Mounjaro injection produces meaningful improvements in cardiometabolic risk factors. Healthcare providers monitoring patients on tirzepatide have documented consistent benefits across multiple parameters in the SURPASS and SURMOUNT programmes:

• Blood pressure: Systolic BP reduction of 6–9 mmHg, comparable to a single antihypertensive medication
• Lipids: Triglyceride reduction of 19–36%, LDL cholesterol reduction of 5–10%, HDL cholesterol increase of 5–8%
• Liver fat: Hepatic fat content reduced by up to 51% in a SURPASS-3 MRI substudy, making tirzepatide a potential treatment for metabolic-associated steatotic liver disease (MASLD)
• Inflammatory markers: C-reactive protein (CRP) reduced by 38–48%, reflecting reduced systemic inflammation
• Waist circumference: Average reduction of 14.5 cm at the 15 mg dose in SURMOUNT-1

The SURPASS-CVOT (cardiovascular outcomes trial) is evaluating tirzepatide’s impact on major adverse cardiovascular events (MACE) in high-risk patients. While results are pending, semaglutide’s SELECT trial demonstrated a 20% MACE reduction, establishing a cardiovascular benefit for the GLP-1 receptor agonist class. Beyond metabolic applications, tirzepatide (as Zepbound) received FDA approval for obstructive sleep apnea in December 2024.

How Does the Mounjaro Injection Compare?

Tirzepatide occupies a specific position in the obesity pharmacotherapy landscape: it currently outperforms approved single-agent prescription medicines on published trial weight-loss outcomes, but is potentially exceeded by next-generation compounds still in development. Most agents in the table below are once-weekly subcutaneous injectables, except for oral semaglutide formulations. Selection between approved options is a clinical decision based on efficacy, tolerability, availability, and cost considerations.

For detailed comparisons, see our weight loss injections comparison guide, CagriSema vs tirzepatide analysis, and survodutide profile.

The Mounjaro Injection in Dubai & the UAE

Tirzepatide (Mounjaro) availability in the UAE is expanding but remains more limited than established options like Saxenda and Ozempic. Healthcare providers in the UAE have been prescribing this once weekly injection since its MoHAP registration. As of early 2026:

• Registration: Mounjaro has received MoHAP registration for type 2 diabetes. The obesity indication (Zepbound) is not yet separately registered in the UAE
• Availability: Available through select hospital pharmacies (Cleveland Clinic Abu Dhabi, Mediclinic, American Hospital Dubai) and specialist endocrinology or obesity management clinics. Not yet widely stocked in community pharmacies
• Prescription: Requires a valid prescription from a licensed endocrinologist, diabetologist, or obesity medicine specialist. Off-label prescribing for weight management is at the clinician’s discretion
• Cost: Approximately AED 1,500–2,500 per month depending on dose and pharmacy. Insurance coverage is typically limited to diabetes indications only
• Supply: Intermittent supply constraints mirror global patterns. Eli Lilly has invested over $18 billion in manufacturing capacity expansion to address global demand

For alternative treatments currently accessible in the UAE, see our Ozempic alternatives in Dubai guide and GLP-1 medications UAE availability and cost overview.

What Happens After Stopping the Mounjaro Injection?

SURMOUNT-4 directly addressed the discontinuation question. After a 36-week open-label tirzepatide run-in (during which participants lost an average of 20.9% body weight—significant weight loss by any measure), patients were randomised to continue tirzepatide or switch to placebo for 52 weeks. Those who switched to placebo regained approximately 14% of body weight, while those who continued tirzepatide lost an additional 5.5%.

The data reinforce the framing of tirzepatide and other GLP-1-based medicines as treatments that address the biological drivers of obesity without permanently correcting them. Discontinuation is associated with weight regain as appetite-regulation mechanisms return toward their pre-treatment state. The published consensus frames these medicines as chronic treatments for a chronic condition, comparable to statins for hyperlipidaemia or antihypertensives for hypertension. Long-term treatment expectations are part of standard prescriber counselling. For a detailed analysis, see the GLP-1 discontinuation and weight regain data review.